Site Editor
Shaji K. Kumar, MD
Shaji K. Kumar, MD
Posted: Tuesday, July 14, 2026
Data on outcomes following subsequent B-cell maturation antigen (BCMA)-targeted treatment in multiple myeloma are limited, prompting investigators to evaluate etentamig, a next-generation BCMA × CD3 bispecific T-cell engager engineered with a bivalent BCMA-binding domain, a low-affinity CD3-binding domain intended to reduce cytokine-release syndrome (CRS), and a silenced Fc region that supports monthly dosing.
Patients with relapsed/refractory multiple myeloma previously treated with BCMA-directed therapies achieved durable responses with etentamig, also known as ABBV-383, in the phase Ib MOVISO study, with encouraging activity observed even after prior BCMA exposure. The findings were presented at the 2026 ASCO Annual Meeting by Saurabh Chhabra, MD, of Mayo Clinic Arizona, Phoenix.
Study Details
The open-label, phase Ib MOVISO trial (ClinicalTrials.gov identifier NCT05650632) enrolled patients with relapsed/refractory multiple myeloma who had received at least two prior lines of therapy, including triple-class therapy, and previous exposure to BCMA-targeted treatment. Eligible patients had received an antibody-drug conjugate more than 30 days or chimeric antigen receptor (CAR) T-cell therapy more than 6 months before study entry. Participants received etentamig at 60 mg on day 1 of cycle 1 without step-up dosing, followed by administration every 4 weeks. The primary safety endpoints were incidence of CRS and immune effector cell–associated neurotoxicity syndrome (ICANS), whereas efficacy endpoints included objective response rate, duration of response, and progression-free survival.
Key Findings
At the data cutoff of June 11, 2025, 41 patients had been treated (24 previously exposed to CAR T-cell therapy and 17 previously treated with a BCMA-directed antibody-drug conjugate). Patients had received a median of six prior lines of therapy, and 81% had triple-class–refractory disease. Slightly more than half (51%) had received a BCMA-directed therapy as their most recent treatment.
The overall response rate was 47%, increasing to 58% among patients whose most recent prior therapy was BCMA-directed. Responses appeared particularly favorable after prior CAR T-cell therapy, with an overall response rate of 50%, increasing to 64% among those whose last prior therapy was BCMA-directed CAR T-cell treatment.
Safety findings were consistent with previous experience. Despite the absence of step-up dosing, CRS occurred in 57% of patients and ICANS in 7%; all CRS events were grade 1 or 2, and only one patient experienced grade 3 ICANS. Grade 3 or 4 neutropenia and infections occurred in 36% and 41% of patients, respectively.
The investigators concluded: “Patients treated with etentamig achieved durable responses; rates were higher in patients who received [CAR T-cell therapy] as last line. No new safety signals were observed; only low-grade CRS was seen despite no step-up dosing.”
DISCLOSURE: For full disclosures of the study authors, visit coi.asco.org.
2026 ASCO Annual Meeting (Abstract 7508)
